Primevera Therapeutics, LLC.
This study explores a potential new treatment for adults with moderate-to-severe asthma using a drug called linvemastat, which targets an enzyme linked to lung inflammation. Despite using standard asthma medications, many patients still struggle with symptoms, so researchers are testing whether linvemastat can improve lung function and reduce flare-ups. In a carefully controlled trial, subjects receive either one of two doses of the drug or a placebo, while continuing their usual treatments. Over 24 weeks, scientists monitor breathing capacity, symptom control, and safety to determine if linvemastat could offer a meaningful new option for asthma management.
This clinical study investigates the potential of a new drug, linvemastat, to improve outcomes for adults with moderate-to-severe asthma who continue to experience symptoms despite using standard treatments like inhaled corticosteroids and long-acting beta-agonists. Linvemastat works by blocking an enzyme called MMP-12, which is believed to contribute to lung inflammation and tissue damage in asthma. The trial is a Phase 2, randomized, double-blind, placebo-controlled study involving approximately 225 subjects \[74 patients per cohort (1:1 active: 1 Placebo)\] across multiple global sites. Sub…
Inclusion Criteria: * Patients aged 18 - 85 years at the time of signing informed consent * Patient is able to provide written informed consent. * Documented physician´s diagnosis of Type 2 high asthma, as per the Global Initiative for Asthma (GINA) 2023 guideline 2023 at Screening. * Patients with existing treatment with at least low to medium doses of ICS therapy in combination with LABA as a second controller for at least 90 days and a stable/optimized dose ≥30 days prior to Day 1. Patients on triple therapy with a long-acting muscarinic antagonist (LAMA) will be excluded. * An ACQ score ≥…
Matrix Metalloproteinase-12 inhibitor
Placebo
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.